Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on March 16, 2021, covering events that occurred on March 15, 2021. The Company is a Nevada corporation with its principal executive offices in La Jolla, California, and its common stock trades on The NASDAQ Stock Market LLC under the symbol "INMB". The filing is designated as an "Other Event" under Item 8.01.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the adoption of Rule 10b5-1 trading plans by specific corporate officers and does not contain financial performance data.
Material Changes
The material event reported is the adoption of Rule 10b5-1 trading plans by three senior executives to facilitate the sale of Company stock. These plans allow insiders to trade shares when they are not in possession of material, non-public information.
- David J. Moss (CFO): Adopted a plan to trade 275,000 shares (approximately 22.48% of his holdings). The plan runs from April 15, 2021, to December 29, 2023.
- Raymond J. Tesi (CEO): Adopted a plan to trade 120,000 shares (approximately 7.79% of his holdings). The plan runs from April 15, 2021, to April 14, 2022.
- Mark Lowdell (CSO): Adopted a plan to trade 120,000 shares (approximately 7.97% of his holdings). The plan runs from April 15, 2021, to April 14, 2022.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, financial guidance, or specific operational risks. The Company explicitly states it does not undertake any obligation to update or report modifications, terminations, or other activities under these plans, except as required by applicable securities laws. Transactions made under these plans will be reported to the SEC in accordance with standard regulations.
Investor Verification Checklist
- Verify the current share ownership percentages of the CFO, CEO, and CSO to confirm the accuracy of the percentages cited in the trading plans.
- Monitor future Form 4 filings to track actual execution of trades under the Moss, Tesi, and Lowdell plans.
- Review the Company's most recent 10-K or 10-Q filings for financial metrics, as this 8-K contains no financial data.
- Check for any subsequent 8-K filings that might report modifications or terminations of these trading plans.